Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Long-acting injectable cabotegravir for the prevention of HIV infection

Long-acting injectable cabotegravir for the prevention of HIV infection Downloaded from http://journals.lww.com/co-hivandaids by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/02/2020 REVIEW URRENT Long-acting injectable cabotegravir for the PINION prevention of HIV infection a b b Meredith E. Clement , Ryan Kofron , and Raphael J. Landovitz Purpose of review This review highlights the development of long-acting injectable cabotegravir (CAB LA) for HIV preexposure prophylaxis (PrEP), with a focus on phase 2 studies and later development. Recent findings Early studies of CAB LA for HIV prevention offered promising pharmacokinetic data and paved the way for phase 2 studies, which have now been completed. On the basis of phase 2 data, dosing of CAB LA at 8- week intervals consistently delivers target trough concentrations in both men and women. Recent studies have shown no required dose adjustments for hepatic or renal disease and minimal drug–drug interactions. Additionally, injectable PrEP is desired by potential PrEP candidates. Still, gaps in knowledge remain with respect to implementation and delivery, the clinical significance of the pharmacologic tail, and dosing in key populations. Phase 3 trials are underway that are anticipated to inform some of these questions and provide efficacy and safety data to support regulatory submissions for CAB LA as a potential PrEP agent. Summary Recent studies have http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in HIV & AIDS Wolters Kluwer Health

Long-acting injectable cabotegravir for the prevention of HIV infection

Download PDF
8 pages

Loading next page...
 
/lp/wolters-kluwer-health/long-acting-injectable-cabotegravir-for-the-prevention-of-hiv-EUI3ljqVZL

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wolters Kluwer Health
ISSN
1746-630X
eISSN
1746-6318
DOI
10.1097/COH.0000000000000597
Publisher site
See Article on Publisher Site

Abstract

Downloaded from http://journals.lww.com/co-hivandaids by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/02/2020 REVIEW URRENT Long-acting injectable cabotegravir for the PINION prevention of HIV infection a b b Meredith E. Clement , Ryan Kofron , and Raphael J. Landovitz Purpose of review This review highlights the development of long-acting injectable cabotegravir (CAB LA) for HIV preexposure prophylaxis (PrEP), with a focus on phase 2 studies and later development. Recent findings Early studies of CAB LA for HIV prevention offered promising pharmacokinetic data and paved the way for phase 2 studies, which have now been completed. On the basis of phase 2 data, dosing of CAB LA at 8- week intervals consistently delivers target trough concentrations in both men and women. Recent studies have shown no required dose adjustments for hepatic or renal disease and minimal drug–drug interactions. Additionally, injectable PrEP is desired by potential PrEP candidates. Still, gaps in knowledge remain with respect to implementation and delivery, the clinical significance of the pharmacologic tail, and dosing in key populations. Phase 3 trials are underway that are anticipated to inform some of these questions and provide efficacy and safety data to support regulatory submissions for CAB LA as a potential PrEP agent. Summary Recent studies have

Journal

Current Opinion in HIV & AIDS – Wolters Kluwer Health

Published: Jan 1, 2020

References

  • Antiretroviral prophylaxis for HIV prevention in heterosexual men and women
    Baeten
  • Preexposure chemoprophylaxis for HIV prevention in men who have sex with men
    Grant
  • Emtricitabine-tenofovir concentrations and preexposure prophylaxis efficacy in men who have sex with men
    Anderson
  • Participants’ explanations for nonadherence in the FEM-PrEP clinical trial
    Corneli
  • Use of modern contraception increases when more methods become available: analysis of evidence from
    Ross
  • Preexposure prophylaxis for HIV prevention preferences among young adult African American men who have sex with men
    Patel
  • The invisible product: preferences for sustained-release, long-acting preexposure prophylaxis to HIV among South African Youth
    Montgomery
  • Selection of rilpivirine-resistant HIV-1 in a seroconverter from the SSAT 040 trial who received the 300-mg dose of long-acting rilpivirine (TMC278LA)
    Penrose
  • Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor
    Spreen
  • GSK1265744 demonstrates robust in vitro activity against various clades of HIV-1
    Karmon
  • Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection
    Yoshinaga
  • Long-acting injectable antiretrovirals for HIV treatment and prevention
    Spreen
  • GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects
    Spreen
  • Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-acting nanosuspensions in healthy adults
    Spreen
  • A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge
    Andrews
  • Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus
    Andrews
  • Cabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251
    Andrews
  • Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans
    Bowers
  • Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam
    Reese
  • Lack of effect of oral cabotegravir on the pharmacokinetics of a levonorgestrel/ethinyl oestradiol-containing oral contraceptive in healthy adult women
    Trezza
  • A phase 1 study to evaluate the pharmacokinetics and safety of cabotegravir in patients with hepatic impairment and healthy matched controls
    Shaik
  • A phase i study to evaluate the pharmacokinetics and safety of cabotegravir in adults with severe renal impairment and healthy matched control participants
    Parasrampuria
  • Effect of a high-fat meal on the pharmacokinetics of the HIV integrase inhibitor cabotegravir
    Patel
  • Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial
    Markowitz
  • Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial
    Landovitz
  • Neural-tube defects and antiretroviral treatment regimens in Botswana
    Zash
  • Drug resistance during HIV pre-exposure prophylaxis
    Gibas
  • Drug resistance emergence in macaques administered cabotegravir long-acting for preexposure prophylaxis during acute SHIV infection
    Radzio-Basu
  • Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk
    Gatell
  • Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial
    van Lunzen
  • Dolutegravir plus two different prodrugs of tenofovir to treat HIV
    Venter
  • Dolutegravir-based or low-dose efavirenz-based regimen for the treatment of HIV-1.
  • Expanding the menu of HIV prevention options: a qualitative study of experiences with long-acting injectable cabotegravir as PrEP in the context of a phase II trial in the United States
    Kerrigan
  • Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: patient perspectives from the ECLAIR trial
    Murray
  • The tablets, ring, injections as options (TRIO) study: what young African women chose and used for future HIV and pregnancy prevention
    van der Straten
  • Interest in long-acting injectable PrEP in a cohort of men who have sex with men in China
    Meyers
  • Lessons for patient education around long-acting injectable PrEP: findings from a mixed-method study of phase ii trial participants
    Meyers
  • Will gay and bisexual men taking oral preexposure prophylaxis (PrEP) switch to long-acting injectable PrEP should it become available?
    John
  • Ending the HIV/AIDS pandemic1
    Eisinger